Cas no 55383-37-4 (Deacetylvinblastine Hydrazide)
Deacetylvinblastine Hydrazide Chemical and Physical Properties
Names and Identifiers
-
- Vincaleukoblastin-23-oicacid, O4-deacetyl-, hydrazide
- Desacetylvinblastine hydrazide
- methyl (3R,5S,7R,9S)-5-ethyl-9-((3aR,3a1R,4R,5S,5aR,10bR)-3a-ethyl-5-(hydrazinecarbonyl)-4,5-dihydroxy-8-methoxy-6-methyl-3a,3a1,4,5,5a,6,11,12-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl)-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methano[1]azacycloundecino[5,4-b]indole-9-carboxylate
- 4-DAVLB-HY
- CHEMBL1288707
- 15-[5-Ethyl-5-hydroxy-9-(methoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundecino[5,4-b]indol-9-yl]-3,4-dihydroxy-16-methoxy-1-methyl-6,7-didehydroaspidospermidine-3-carbohydrazonic acid
- UNII-F593MEE9K3
- Deacetylvinblastine hydrazide
- DTXSID90970723
- Vincaleukoblastin-23-oic acid, O(sup 4)-deacetyl-, hydrazide
- DEACETYLVINBLASTINE HYDRAZIDE [EP IMPURITY]
- desacetylvinblastine-3-carboxylic acid hydrazide
- SCHEMBL17529277
- DAVLBH
- 4-desacetylvinblastine-3-carboxhydrazide
- O4-DEACETYL-23-DEMETHOXY-23-HYDRAZINYLVINCALEUKOBLASTINE
- F593MEE9K3
- 55383-37-4
- VINDESINE SULFATE IMPURITY C [EP IMPURITY]
- 4-Desacetylvinblastine hydrazide
- SCHEMBL19124869
- AKOS040749968
- methyl (13S,15R,17S)-17-ethyl-13-[(1R,9R,10S,11R,12R,19R)-12-ethyl-10-(hydrazinecarbonyl)-10,11-dihydroxy-5-methoxy-8-methyl-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraen-4-yl]-17-hydroxy-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraene-13-carboxylate
- O(sup 4)-Deacetyl-vincaleukoblastin-23-oic acid hydrazide
- Deacetylvinblastine Hydrazide
-
- Inchi： 1S/C43H56N6O7/c1-6-39(53)21-25-22-42(38(52)56-5,33-27(13-17-48(23-25)24-39)26-11-8-9-12-30(26)45-33)29-19-28-31(20-32(29)55-4)47(3)35-41(28)15-18-49-16-10-14-40(7-2,34(41)49)36(50)43(35,54)37(51)46-44/h8-12,14,19-20,25,34-36,45,50,53-54H,6-7,13,15-18,21-24,44H2,1-5H3,(H,46,51)/t25-,34-,35+,36+,39-,40+,41+,42-,43-/m0/s1
- InChI Key： PPRGGNQLPSVURC-ZVTSDNJWSA-N
- SMILES： O[C@]1(C(NN)=O)[C@@H]([C@@]2(C=CCN3CC[C@@]4(C5C=C([C@]6(C(=O)OC)C7=C(C8C=CC=CC=8N7)CCN7C[C@](CC)(C[C@H](C7)C6)O)C(=CC=5N(C)[C@H]41)OC)[C@@H]32)CC)O
Computed Properties
- Exact Mass: 768.421048
- Monoisotopic Mass: 768.421048
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 6
- Hydrogen Bond Acceptor Count: 11
- Heavy Atom Count: 56
- Rotatable Bond Count: 7
- Complexity: 1590
- Covalently-Bonded Unit Count: 1
- Defined Atom Stereocenter Count: 9
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- XLogP3: 2.9
- Topological Polar Surface Area: 177
Experimental Properties
- Color/Form: No data available
- Density: 1.4±0.1 g/cm3
- Melting Point: >240°C (dec.)
- Boiling Point: Not available
- Flash Point: Not available
- Refractive Index: 1.711
- Vapor Pressure: Not available
Deacetylvinblastine Hydrazide Security Information
- Signal Word：warning
- Hazard Statement： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
-
Warning Statement：
P264Thoroughly clean after treatment
P280Wear protective gloves/Wear protective clothing/Wear protective goggles/Wear a protective mask
P305If it enters the eyes
P351Rinse carefully with water for a few minutes
P338Remove the contact lens(If any)And easy to operate,Continue flushing
P337If eye irritation persists
P313Obtain medical advice/care - Safety Instruction： H303May be harmful if swallowed+H313Skin contact may be harmful+H333Inhalation may be harmful to the body
- Storage Condition：storage at -4℃ (1-2weeks), longer storage period at -20℃ (1-2years)
Deacetylvinblastine Hydrazide Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| TRC | D199065-1mg |
Deacetylvinblastine Hydrazide |
55383-37-4 | 1mg |
$ 241.00 | 2023-09-08 | ||
| TRC | D199065-2.5mg |
Deacetylvinblastine Hydrazide |
55383-37-4 | 2.5mg |
$ 471.00 | 2023-09-08 | ||
| TRC | D199065-5mg |
Deacetylvinblastine Hydrazide |
55383-37-4 | 5mg |
$ 874.00 | 2023-09-08 | ||
| TRC | D199065-10mg |
Deacetylvinblastine Hydrazide |
55383-37-4 | 10mg |
$1608.00 | 2023-05-18 |
Deacetylvinblastine Hydrazide Related Literature
-
Yiding Jiao,Liqun Kang,Jasper Berry-Gair,Kit McColl,Jianwei Li,Haobo Dong,Hao Jiang,Ryan Wang,Furio Corà,Dan J. L. Brett,Ivan P. Parkin J. Mater. Chem. A, 2020,8, 22075-22082
-
Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
-
Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
-
Chen Long,Ying Dai,Jianwei Li,Hao Jin Nanoscale, 2020,12, 21124-21130
-
Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
Additional information on Deacetylvinblastine Hydrazide
Deacetylvinblastine Hydrazide (CAS No. 55383-37-4): A Comprehensive Overview
Deacetylvinblastine Hydrazide (CAS No. 55383-37-4) is a semi-synthetic derivative of vinblastine, a naturally occurring alkaloid derived from the Catharanthus roseus plant. This compound has garnered significant attention in the pharmaceutical and research communities due to its unique structural modifications and potential therapeutic applications. The hydrazide functional group in Deacetylvinblastine Hydrazide enhances its solubility and bioavailability, making it a promising candidate for further development.
The chemical structure of Deacetylvinblastine Hydrazide features a complex indole alkaloid framework, which is characteristic of the vinca alkaloid family. The compound's molecular formula is C46H58N6O8, and it has a molecular weight of 822.99 g/mol. Researchers are particularly interested in its mechanism of action, which involves the inhibition of microtubule formation, a property it shares with its parent compound, vinblastine. This mechanism is crucial for its potential applications in cancer therapy and other cell proliferation-related disorders.
In recent years, the demand for Deacetylvinblastine Hydrazide has increased due to its role in drug discovery and pharmaceutical research. Scientists are exploring its efficacy in combination therapies, particularly in the treatment of resistant cancers. The compound's ability to overcome drug resistance mechanisms has made it a subject of intense study, especially in the context of personalized medicine and targeted therapy.
The synthesis of Deacetylvinblastine Hydrazide involves the deacetylation of vinblastine followed by the introduction of a hydrazide group. This modification not only improves the compound's pharmacokinetic properties but also reduces its toxicity profile compared to vinblastine. These advancements align with the growing trend in the pharmaceutical industry to develop safer and more effective derivatives of existing drugs.
From a market perspective, Deacetylvinblastine Hydrazide is primarily used in research laboratories and pharmaceutical development projects. Its niche applications include anticancer drug formulation and cell biology studies. The compound is typically supplied as a high-purity powder, ensuring consistency and reliability for experimental use. Suppliers often highlight its stability under controlled storage conditions, which is a critical factor for researchers.
One of the most frequently asked questions about Deacetylvinblastine Hydrazide relates to its bioavailability and metabolic pathways. Studies have shown that the hydrazide moiety enhances its absorption and distribution in biological systems, making it a more efficient candidate for oral administration. This property is particularly relevant in the context of patient compliance and outpatient treatment regimens.
Another area of interest is the compound's potential role in immunotherapy. Preliminary research suggests that Deacetylvinblastine Hydrazide may modulate immune responses, opening new avenues for its use in combination immunotherapies. This aligns with the current focus on immune-oncology, a rapidly evolving field that seeks to harness the body's immune system to fight cancer.
In terms of safety, Deacetylvinblastine Hydrazide has been evaluated in various preclinical models. While it exhibits a favorable toxicity profile compared to vinblastine, researchers emphasize the need for further clinical studies to fully understand its side effects and long-term impacts. These studies are essential for its potential transition from the lab to the clinic.
The global market for Deacetylvinblastine Hydrazide is expected to grow steadily, driven by increasing investments in cancer research and drug development. Key players in the pharmaceutical industry are actively exploring its commercial potential, particularly in regions with high incidences of cancer. This trend underscores the compound's significance in modern medicine.
For researchers and suppliers, understanding the regulatory requirements for Deacetylvinblastine Hydrazide is crucial. The compound is subject to standard laboratory safety protocols, and its use in human therapeutics requires compliance with Good Manufacturing Practices (GMP) and other relevant guidelines. These considerations are vital for ensuring its safe and effective application.
In conclusion, Deacetylvinblastine Hydrazide (CAS No. 55383-37-4) represents a promising advancement in the field of medicinal chemistry. Its unique properties and potential applications make it a valuable tool for researchers and a candidate for future therapeutic development. As the scientific community continues to explore its capabilities, Deacetylvinblastine Hydrazide is poised to play a significant role in the next generation of cancer treatments and biomedical innovations.
55383-37-4 (Deacetylvinblastine Hydrazide) Related Products
- 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
- 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
- 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
- 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
- 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
- 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
- 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
Audited Supplier
